AU2021217378A1 - Methods for the treatment of scleroderma and related conditions - Google Patents

Methods for the treatment of scleroderma and related conditions Download PDF

Info

Publication number
AU2021217378A1
AU2021217378A1 AU2021217378A AU2021217378A AU2021217378A1 AU 2021217378 A1 AU2021217378 A1 AU 2021217378A1 AU 2021217378 A AU2021217378 A AU 2021217378A AU 2021217378 A AU2021217378 A AU 2021217378A AU 2021217378 A1 AU2021217378 A1 AU 2021217378A1
Authority
AU
Australia
Prior art keywords
amino acid
igf
seq
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021217378A
Other languages
English (en)
Inventor
Srini RAMANATHAN
Elizabeth Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horizon Therapeutics Ireland DAC
Original Assignee
Horizon Therapeutics Ireland DAC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Ireland DAC filed Critical Horizon Therapeutics Ireland DAC
Publication of AU2021217378A1 publication Critical patent/AU2021217378A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021217378A 2020-02-04 2021-02-04 Methods for the treatment of scleroderma and related conditions Abandoned AU2021217378A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062970063P 2020-02-04 2020-02-04
US62/970,063 2020-02-04
US202063049522P 2020-07-08 2020-07-08
US63/049,522 2020-07-08
PCT/US2021/016666 WO2021158823A1 (en) 2020-02-04 2021-02-04 Methods for the treatment of scleroderma and related conditions

Publications (1)

Publication Number Publication Date
AU2021217378A1 true AU2021217378A1 (en) 2022-09-01

Family

ID=77200418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021217378A Abandoned AU2021217378A1 (en) 2020-02-04 2021-02-04 Methods for the treatment of scleroderma and related conditions

Country Status (11)

Country Link
US (2) US20210253686A1 (cg-RX-API-DMAC7.html)
EP (1) EP4100127A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023515771A (cg-RX-API-DMAC7.html)
KR (1) KR20220151619A (cg-RX-API-DMAC7.html)
CN (1) CN115397518A (cg-RX-API-DMAC7.html)
AU (1) AU2021217378A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015447A2 (cg-RX-API-DMAC7.html)
CA (1) CA3169994A1 (cg-RX-API-DMAC7.html)
IL (1) IL295372A (cg-RX-API-DMAC7.html)
MX (1) MX2022009628A (cg-RX-API-DMAC7.html)
WO (1) WO2021158823A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025519600A (ja) * 2022-06-10 2025-06-26 アセリリン, インコーポレイテッド 抗igf-1r抗体組成物
KR20250048156A (ko) * 2022-06-29 2025-04-07 리룸 테라퓨틱스, 인크. 제제에 접합된 인슐린 유사 성장 인자 1 수용체 리간드를 사용한 자가면역 질환의 치료
WO2025007015A2 (en) * 2023-06-30 2025-01-02 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for multiple sclerosis
WO2025007012A2 (en) * 2023-06-30 2025-01-02 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for rheumatoid arthritis
CN119548621A (zh) * 2023-09-01 2025-03-04 苏州普乐康医药科技有限公司 抗igf-1r抗体或其抗原结合部分在减重中的应用
WO2025155894A1 (en) * 2024-01-19 2025-07-24 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for fibrotic diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596854A4 (en) * 2003-02-14 2007-06-06 Childrens Hosp & Res Ct Oak TREATMENT OF DISEASES RELATED TO REDUCED STICK OXIDE BIOVERABILITY, INCLUDING INCREASED ARGINASE
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2008144720A2 (en) * 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders
WO2010028274A1 (en) * 2008-09-05 2010-03-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation
JP2012505900A (ja) * 2008-10-14 2012-03-08 ダイアクス コーポレーション 全身性強皮症に伴う肺線維症の治療および予防のためのigf−ii/igf−iie結合タンパク質の使用
EP2785382B1 (en) * 2011-12-02 2019-01-02 IBC Pharmaceuticals, Inc. Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
EP2647994A1 (en) * 2012-04-03 2013-10-09 Universitätsklinikum Freiburg Method for diagnosis of pulmonary involvement in systemic sclerosis
CN107982247A (zh) * 2018-01-23 2018-05-04 中日友好医院 二甲双胍在制备治疗肺纤维化药物中的应用
EP3752161A4 (en) * 2018-02-15 2021-12-22 Children's Hospital Medical Center METHOD OF TREATMENT OF FIBROSE

Also Published As

Publication number Publication date
KR20220151619A (ko) 2022-11-15
EP4100127A4 (en) 2024-02-28
IL295372A (en) 2022-10-01
EP4100127A1 (en) 2022-12-14
US20210253686A1 (en) 2021-08-19
MX2022009628A (es) 2022-11-07
US20240279323A1 (en) 2024-08-22
WO2021158823A1 (en) 2021-08-12
CN115397518A (zh) 2022-11-25
BR112022015447A2 (pt) 2022-11-16
CA3169994A1 (en) 2021-08-12
JP2023515771A (ja) 2023-04-14

Similar Documents

Publication Publication Date Title
US20240279323A1 (en) Methods for the treatment of scleroderma and related conditions
US12600787B2 (en) Methods for the treatment of thyroid eye disease
US20210379183A1 (en) METHODS OF TREATING IgA NEPHROPATHY WITH AN APRIL BINDING ANTIBODY
EP4301410A1 (en) Methods for the treatment of thyroid eye disease
US20230270851A1 (en) Methods for the treatment of idiopathic orbital inflammation and related conditions
US20240059783A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
TW202434633A (zh) 治療甲狀腺眼疾之方法
JP2025519600A (ja) 抗igf-1r抗体組成物
EP4526353A2 (en) Formulations for anti-insulin receptor antibody and uses thereof
US20230009657A1 (en) Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
KR20260036536A (ko) 다발성 경화증 치료를 위한 조성물 및 방법
EP4516314A1 (en) Combination of anti-pd-1 antibody and anti-egfr antibody, and use thereof in treatment of head and neck squamous cell carcinoma
KR20240099411A (ko) 항-cd38 항체를 사용한 치료에서 코르티코스테로이드 감소
US12037387B2 (en) PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa
KR20250011951A (ko) 인터루킨-17 (il-17) 길항제를 사용한 거대 세포 동맥염의 치료 방법
CA3234180A1 (en) Methods for treating multiple myeloma
CN117813328A (zh) 用于治疗儿童ms的奥法妥木单抗
CN120000779A (zh) 抗il-5抗体治疗与嗜酸性粒细胞升高相关疾病的用途

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period